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Abstract 
Background : To determine the validity of 
transcutaneous bilirubinometer, keeping laboratory 
serum bilirubin level as gold standard and to 
compare bilirubin levels by both methods after 
treatment i.e. phototherapy and exchange transfusion 
in the evaluation of neonatal jaundice. 
Methods: In this cross sectional study serum 
samples of 122  neonates, up to 01 week of age, of 
either sex, having visible clinical jaundice were sent 
to pathology laboratory for total bilirubin estimation. 
 At the same time, total bilirubin level was checked 
and recorded by a BiliCheck Jaundice Meter. 
Results: Before start of treatment serum bilirubin 
values ranged from 150-300mol with mean of 
220mol while transcutaneous bilirubin values 
ranged from 155-320mol with mean of 229mol. The 
bilirubin value obtained by transcutaneous 
bilirubinometer does not differ significantly from 
laboratory serum bilirubin measurement before 
treatment.   
Conclusion: Bilicheck Transcutaneous 
Bilirubinometer, as a screening device, offers an 
accurate, rapid, economic and noninvasive means of 
assessing plasma bilirubin concentrations in 
neonates. 
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Introduction 
    Jaundice (icterus)  is the most common condition 
that requires medical attention in neonates. In most 
neonates, unconjugated hyperbilirubinemia reflects a 
normal transitional phenomenon.In some neonates, 
serum unconjugated bilirubin levels may excessively 
rise,which is neurotoxic and may lead to hearing loss, 
gaze abnormality, athetoid cerebral palsy and mental 
retardation.1-4 Typically, the concentration of bilirubin 
in the plasma must exceed 1.5 mg/dL, three times the 
usual value of approximately 0.5mg/dl, for the 
coloration to be easily visible. Early recognition of 
hyperbilirubinemia is of cardinal significance and 
requires evaluation in the form of noninvasive and 
inexpensive screening. The bilirubin level, may be 
measured either in the serum or noninvasively via 
transcutaneous bilirubinometry. 5,6   
     Frequent blood sampling, for serum bilirubin 
estimation, may cause anemia especially in premature 
newborns.  Blood sampling is a painful procedure and 
can increase the risk of infection and scar formation.  
Using other methods of bilirubin estimation is 
important for the prevention of these devastating 
complications.  A study suggests that 20-50% 
reduction in samples collected for bilirubin analysis 
could be achieved after implementation of 
transcutaneous bilirubin measurements. 
Transcutaneous bilirubinometry is a safe and effective 
technique for screening of hyperbilirubinemia in 
neonates.7-11 It is easy to use and non-invasive method 
to estimate the level of bilirubin. Transcutaneous 
bilirubin measurements correlate with serum bilirubin 
estimation in neonates that permit non invasive and 
rapid measurements. The accuracy of transcutaneous 
bilirubinometry for bilirubin estimation and its role in 
the prevention of frequent blood sampling in term 
infants have been established.  Bilirubin values 
obtained by transcutaneous bilirubinometer were not 
significantly different from laboratory values thus 
proving the fact that transcutaneous bilirubinometer is 
a useful device to measure bilirubin. 12-14 Since the last 
two decades, an electronic device by the name of Air 
Shield Jaundice Meter has been manufactured, as a 
joint effort by the researchers at Okajama medical 
centre Japan and the Minolta Camera Ltd. Moreover, 
in last two years, SpectR(x) of USA has also marketed 
another transcutaneous bilirubin measuring device by 
the name of Bilicheck.  The performance of Bilicheck is 
highly influenced by the measurement site.  The 
forehead is the most frequent site of transcutaneous 
bilirubin measurement in clinical practice.15,16   
Patients and Methods 
     This study was carried out from June, 2008 to  Nov, 
2008 in the Neonatal Intensive Care Unit of Holy 
Family Hospital Rawalpindi. Total 122 neonates  up to 
01 week of age, having visible clinical jaundice 
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reporting to neonatology unit of Holy Family Hospital 
Rawalpindi were subjected to the clinical study.   
Before start of treatment, transcutaneous 
measurements were taken by application of Bilicheck 
to the forehead of infants. Three such readings were 
taken and the average value recorded. Blood samples 
were obtained from a peripheral vein under strict 
aseptic conditions within 10 minutes of transcutaneous 
bilirubin measurements. Transcutaneous bilirubin and 
Serum bilirubin levels were retaken during treatment 
with Phototherapy or exchange transfusion to 
compare both levels. Serum bilirubin was estimated by 
an automated  spectrophotometer. Total Serum 
Bilirubin was analyzed using Merckotest kit 
(Germany) , based on DPD 
(dichlorophenyldiazonium) method, at a wavelength 
of 546nm. The neonates were then given treatment, 
either with Phototherapy or Exchange transfusion and 
their serum & transcutaneous bilirubin levels were re-
estimated 
 
Results 
     122 neonates were included in the study over a 
period extending from June 2008 - November 2008. 
Their ages ranged from 1-7 days, with mean of 3.5 
days. Regarding sex, 66 male and 56 female neonates 
were included. Their weights ranged from 2.5 - 3.5 kg, 
with 74% lying between 2.5-3.0 kg. 
  
Table 1: Bilirubin levels (mol) before 
start of treatment (n = 122) 
 Serum Bilirubin from 
Laboratory  
Transcutaneous 
Bilirubin (by 
Bilicheck) 
Mean 220.86 229.75 
SD 37.481 41.595 
Minimum 150 155 
Maximum 300 320 
 
Table 2:   Test statistics before treatment  
 Serum 
bilirubin  
Transcutaneous 
bilirubin   
Chi-square   a 
df 
Asymp.Sig. 
40.557 
3 
.00 
29.279 
3 
.00 
p < 0.05 is statistically significant  
 
Table 3: Neonatal Jaundice- Treatment (n=122) 
Treatment Options No(%) 
Phototherapy 89(73) 
Exchange Transfusion 33(27) 
     The 122 serum samples sent to laboratory for 
bilirubin estimation before start of treatment, revealed 
bilirubin value between 150mol - 300mol with mean 
of 220mol, having standard deviation of 37.48. 
Similarly, the transcutaneous bilirubin (By Bilicheck) 
values before starting treatment ranged between 155-
320mol with mean of 229mol, having standard 
deviation of 41.595 (Table 1). Test statistics showed a 
good coefficient of correlation between bilirubin 
values obtained by bilicheck and those received from 
laboratory with p- value 0.00 (Table 2). Majority (73%) 
of neonates were given the phototherapy while 27% 
needed exchange transfusion (Table 3). 
     After treatment, the serum bilirubin values ranged 
from 50-160mol, with mean of 88.93mol having 
standard deviation of 23.516. The transcutaneous 
bilirubin values ranged from 55- 190mol, with mean 
of 105.94mol having standard deviation of 25.619 
(Table 4).  After treatment bilirubin levels estimated 
transcutaneously and in the serum are statistically 
significant with P value 0.00 (Table 5).   Bilirubin value 
obtained by transcutaneous bilirubinometer do not 
differ significantly from laboratory serum bilirubin 
measurement before treatment. However, serum 
bilirubin levels are still required, when treatment with 
phototherapy or exchange transfusion is being 
considered. 
Table 4:   Bilirubin levels (mol) after treatment 
(n = 122) 
 Serum Bilirubin 
from Lab 
Transcutaneous (by 
Bilicheck) 
Mean 88.93 105.94 
SD 23.516 25.619 
Minimum 50 55 
Maximum 160 190 
 
 Table 5: Test statistics after treatment 
 Serum bilirubin  Transcutaneous 
bilirubin  
Chi-square      a 
df 
Asymp.sig. 
 
97.984 
2 
.00 
41.918 
2 
.00 
P < 0.05 is statistically significant 
    
Discussion 
     Neonatal jaundice contributes to a major share of 
admissions in the neonatal intensive care units. 
Transcutaneous bilirubinometers are widely used in 
the developed countries of the world and are subjected 
to continuous research in regard to their comparison 
with serum bilirubin estimation. Present study showed 
a good Coefficient of Correlation (p=0.00) between the 
bilirubin values obtained by Bilicheck and those 
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received from Laboratory.  Laeeq A et al (1993) 
performed simultaneous estimation of serum and 
transcutaneous bilirubin measurements on 105 full 
term jaundiced newborns. Their results revealed a 
good correlation between transcutaneous and serum 
bilirubin values. 17 If screening by transcutabeous 
bilirubin indicates that a neonate is at increased risk 
for clinically significant hyperbilirubinemia, serum 
bilirubin should be measured.18   Bilicheck can be 
safely used for the evaluation of bilirubin levels in 
newborn infants under phototherapy. However, it 
cannot be used directly to make decisions about 
exchange transfusion or phototherapy in neonates.19,20  
     In the present study, the bilirubin values obtained 
by transcutaneous bilirubinometer do not differ 
significantly from laboratory serum bilirubin 
measurement before treatment. However, serum 
bilirubin levels were still required, when treatment 
with phototherapy or exchange transfusion was being 
considered. TcB measurement provides a good 
estimate of the bilirubin level, as with any laboratory 
measurement. It is important to consider the relevant 
risk factors for jaundice when making decisions about 
follow-up or intervention.21-23    
 
Conclusion 
1.Using predetermined TcB cut-off values with 
reasonable sensitivity and specificity, transcutaneous 
bilirubinometer is a useful screening tool to identify 
infants with TSB ≥ 300 µmol/L, requiring blood 
sampling, hospital admission and treatment. 
2. While contemplating exchange transfusion and 
phototherapy spectrophotometric bilirubin estimation 
will be required    
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